European Journal of Biomedical and Pharmaceutical Sciences

OLANZAPINE INDUCED HEMOTOXICITY: A CASE REPORT IN PSYCHIATRY DEPARTMENT

Dr. Venkataramudu, G. Ramya Sree*, M. Jeevana Sravanthi, M. Sam Jeeva Kumar, C. Veera Vamsi

ABSTRACT

Olanzapine is a second generation (atypical) anti-psychotic medication, widely used for the treatment of schizophrenia and bipolar disorder. In comparision to conventional or other medications, atypical anti psychotics have safety advantages including less sedation, cardiovascular effects, postural instability, falls and movement disorders. Olanzapine induced hematoxicity is a rare adverse effect that is currently poorly described in literature. We present a rare case of hemotoxicity induced by Olanzapine of 10mg/day in a 40 year old female patient with the diagnosis of BPAD. In this case we have observed a gradual decrease of total WBC and Lymphocytes from first week to 6th week of treatment, in similar way observed an increase in eosinophil count. However, these haematological adverse effects were resolved by the discontinuation of olanzapine treatment. Although monitoring blood counts during antipsychotics use is not recommended, clinicians should be aware of this rare but hazardous side effect. Suspected ADR was probable ADR (Naranjo’s scale).

Keywords: BPAD (Bipolar affective disorder), WBC (White blood cells), ADR( Adverse drug reaction), Hemotoxicity, Olanzapine.